Design, green synthesis and pharmacological evaluation of novel 5,6-diaryl-1,2,4-triazines bearing 3-morpholinoethylamine moiety as potential antithrombotic agents^*

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:e28–292
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2008;8:1227–34
   Web of Science ®Google Scholar
• Lau WC, Gurbel PA. Antiplatelet drug resistance and drug–drug interactions: role of cytochrome P450 3A4. Pharm Res 2006;23:2691–708
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606–17
   PubMed Web of Science ®Google Scholar
• Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813–18
   PubMed Web of Science ®Google Scholar
• DeWitt DL, Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990;265:5192–8
   PubMed Web of Science ®Google Scholar
• Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005;112:759–70
   PubMed Web of Science ®Google Scholar
• Talley JJ. Selective inhibitors of cyclooxygenase-2 (COX-2). Prog Med Chem 1999;36:201–34
   PubMed Web of Science ®Google Scholar
• Rynbrandt RH, Nishizawa EE, Balgoyen DP, et al. Synthesis and platelet aggregation inhibitory activity of 4,5-bis(aryl)-2-substituted-thiazoles. J Med Chem 1981;24:1507–10
   PubMed Web of Science ®Google Scholar
• Almansa C, de Arriba AF, Cavalcanti FL, et al. Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines. J Med Chem 2001;44:350–61
   PubMed Web of Science ®Google Scholar
• Meanwell NA, Rosenfeld MJ, KimWright JJ, et al. Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]-phenoxy]acetic acid substituted alpha to the oxazole ring. J Med Chem 1993;36:3871–83
   PubMed Web of Science ®Google Scholar
• Qiao JX, Wang TC, Ruel R, et al. Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1′-neo-pentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4(trifluoromethoxy)phenyl)-urea, a potent, selective, and bioavailable P2Y1 antagonist. J Med Chem 2013;56:9275–95
   PubMed Web of Science ®Google Scholar
• Campillo N, Garcıa C, Goya P, et al. Novel arylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides as inhibitors of platelet aggregation. J Med Chem 1999;42:1698–704
   PubMed Web of Science ®Google Scholar
• (a) Tanaka A, Sakai H, Motoyama Y, et al. Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis: evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. J Med Chem 1994;37:1189–99. (b) Tanaka A, Sakai H, Ishikawa T, et al. Studies on anti-platelet agents: V. Synthesis and structure–activity relationship of 3-substituted 5,6-bis(4-methoxyphenyl)-1,2,4-triazines. Chem Pharm Bull (Tokyo) 1994;42:1835–40
   Google Scholar
• Bode-Böger SM, Boger RH, Galland A, et al. L-Arginine-induced vasodilation in healthy humans: pharmacokinetic–pharmacodynamic relationship. Br J Clin Pharmacol 1998;46:489–97
   PubMed Web of Science ®Google Scholar
• Steinmetzer T, Batdorsdhjin M, Kleinwachter P, et al. New thrombin inhibitors based on D-cha-Pro-derivatives. J Enzyme Inhib 1999;14:203–16
   PubMed Web of Science ®Google Scholar
• Sudo Y, Lucchesi BR. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. J Cardiovasc Pharmacol 1996;27:545–55
   PubMed Web of Science ®Google Scholar
• Rachlin S, Bramm E, Ahnfelt-Roenne I, et al. Basic anti-inflammatory compounds. N,N′,N″-trisubstituted guanidines. J Med Chem 1980;23:13–20
   PubMed Web of Science ®Google Scholar
• Xian M, Li X, Tang X, et al. N-hydroxyl derivatives of guanidine based drugs as enzymatic NO donors. Bioorg Med Chem Lett 2001;11:2377–80
   PubMed Web of Science ®Google Scholar
• CAST (The Cardiac Arrhythmia Suppression Trial II) investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992;327:227–33
   PubMedGoogle Scholar
• Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 1996;52:450–74
   PubMed Web of Science ®Google Scholar
• Medvedev VE, Trosnova AP, Dobrovolskii AV. Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole. Zh Nevrol Psikhiatr Im S S Korsakova 2007;107:25–9
   PubMedGoogle Scholar
• Dunbar JE, Begin LE. Aminoalkylsulfides, aminoalkylsulfoxides and aminoalkylslfones. US Patent US4281118, USA; 1981
   Google Scholar
• Kadin SB. Antiulcer thiazol-2-ylcarbamoyl-carboxylic acids, esters and amides, US Patent US4321372, USA; 1982
   Google Scholar
• Konno S, Kokubo T, Amano M, et al. Studies on as-triazine derivatives. XVIII. Synthesis of 5,6-diaryl-1,2,4-triazine derivatives as blood platelet aggregation inhibitors. Yakugaku Zasshi 1992;112:729–41
   Google Scholar
• Abdel-Rahman RM. Role of uncondensed 1,2,4-triazine compounds and related heterobicyclic systems as therapeutic agents – a review. Pharmazie 2001;56:18–22
   PubMed Web of Science ®Google Scholar
• Monge A, Palop J, Ramirez C, et al. New 5H-1,2,4-triazino[5,6-b]indole and aminoindole derivatives: synthesis and studies as inhibitors of blood platelet aggregation, anti-hypertensive agents and thromboxane synthetase inhibitors. Eur J Med Chem 1991;26:179–88
   Web of Science ®Google Scholar
• O'Rourke M, Lang Jr SA, Cohen E. 3-Aryl-as-triazines as potential antiinflammatory agents. J Med Chem 1977;20:723–6
   PubMed Web of Science ®Google Scholar
• Ban K, Duffy S, Khakham Y, et al. 3-Alkylthio-1,2,4-triazine dimers with potent antimalarial activity. Bioorg Med Chem Lett 2010;20:6024–9
   PubMed Web of Science ®Google Scholar
• Khoshneviszadeh M, Ghahremani MH, Foroumadi A, et al. Design, synthesis and biological evaluation of novel anti-cytokine 1,2,4-triazine derivatives. Bioorg Med Chem 2013;21:6708–17
   PubMed Web of Science ®Google Scholar
• Congreve M, Andrews SP, Doré AS, et al. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem 2012;55:1898–903
   PubMed Web of Science ®Google Scholar
• Ansari N, Khodagholi F, Ramin M, et al. Inhibition of LPS-induced apoptosis in differentiated-PC12 cells by new triazine derivatives through NF-κB-mediated suppression of COX-2. Neurochem Int 2010;57:958–68
   PubMed Web of Science ®Google Scholar
• Irannejad H, Amini M, Khodagholi F, et al. Synthesis and in vitro evaluation of novel 1,2,4-triazine derivatives as neuroprotective agents. Bioorg Med Chem 2010;18:4224–30
   PubMed Web of Science ®Google Scholar
• Sinha A, Tamboli RS, Seth B, et al. Neuroprotective role of novel triazine derivatives by activating wnt/β catenin signaling pathway in rodent models of alzheimer's disease. Mol Neurobiol 2014. [Epub ahead of print]. doi: 10.1007/s12035-014-8899-y
   PubMed Web of Science ®Google Scholar
• (a) Lacefield WB. 5,6-Diaryl-1,2,4-triazines as topical antithrombotic agents. US Patent US4318911A, USA; 1982; (b) Lacefield WB. 5,6-Diaryl-1,2,4-triazines. US Patent US4190725, USA; 1977
   Google Scholar
• Ramajayam R, Giridhar R, Yadav MR, et al. Synthesis, antileukemic and antiplatelet activities of 2,3-diaryl-6,7-dihydro-5H-1,4-diazepines. Eur J Med Chem 2008;43:2004–10
   PubMed Web of Science ®Google Scholar
• Giridhar R, Tamboli RS, Ramajayam R, et al. Assessment of antiplatelet activity of 2-aminopyrimidines. Eur J Med Chem 2012;50:428–32
   PubMed Web of Science ®Google Scholar
• Tamboli RS, Giridhar R, Mande HM, et al. Room-temperature ionic liquid–DMSO promoted and improved one-pot synthesis of 5,6-diaryl-1,2,4-triazines. Synth Commun 2014;44:2192–204
   Web of Science ®Google Scholar
• Broersma RJ, Kutcher LW, Heminger EF. The effect of thrombin inhibition in a rat arterial thrombosis model. Thromb Res 1991;64:405–12
   PubMed Web of Science ®Google Scholar
• Hara T, Yokoyama A, Tanabe K, et al. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995;74:635–9
   PubMed Web of Science ®Google Scholar
• Döttl K, Ripke O. Blutgerinnung und blutungszeit. In: Medizin und chemie. Leverkusen, Germany: Bayer; 1936:267–73
   Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91
   PubMed Web of Science ®Google Scholar
• (a) Sanner MF. Python: a programming language for software integration and development. J Mol Graphics Mod 1999;17:57–61. (b) Sanner MF, Spehner JC, Olson AJ. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 1996;38:305–20
   Google Scholar
• (a) Shirude ST, Patel PJ, Giridhar R, et al. An efficient and time saving microwave-assisted selenium dioxide oxidation of 1,2-diarylethanones. Indian J Chem 2006;45B:1080–5. (b) Yadav MR, Shirude ST, Puntambekar DS, et al. Studies in 3,4-diaryl-1,2,5-oxadiazoles and their N-oxides: search for better COX-2 inhibitors. Acta pharm 2007;57:13–30
   Google Scholar
• (a) Harman CA, Turman, MV, Kozak KR, et al. Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J Biol Chem 2007;282:28096–105. (b) Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644–8
   Google Scholar
• Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;1:1075–8
   Web of Science ®Google Scholar